Cotinga Pharmaceuticals Inc COTQF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.01
- Market Cap
- $2,198.64
- Volume/Avg
- 6,500 / 6,500
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- http://www.cotingapharma.com
Valuation
|
Metric
|
COTQF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
COTQF
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.05 |
Interest Coverage | −97.21 |
Quick Ratio
COTQF
Profitability
|
Metric
|
COTQF
|
|---|---|
Return on Assets (Normalized) | −213.37% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
COTQF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zvdzkpfxd | Qqc | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cpwmgqrcc | Qtsltt | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rzncxszx | Yzsfb | $106.0 Bil | |
MRNA
| Moderna Inc | Jrpbmgrmt | Wsf | $46.4 Bil | |
ARGX
| argenx SE ADR | Knskhgysw | Pmwdd | $23.2 Bil | |
BNTX
| BioNTech SE ADR | Txdwyyd | Bhf | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wmyhxbn | Nsqlkx | $19.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bgsbznbj | Kmnyttx | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ztncdlcsgg | Nzfcwp | $12.7 Bil | |
INCY
| Incyte Corp | Vvjybdjkr | Bdcdmc | $12.2 Bil |